Glioblastoma stem cell–derived tumor-associated antigens (GSC-TAAs)

Glioblastoma stem cell–derived tumor-associated antigens (GSC-TAAs) are a specific class of proteins expressed by glioblastoma stem cells (GSCs), a subpopulation of cells within glioblastoma multiforme (GBM) that possess self-renewal capabilities and high tumorigenic potential (Bao et al., 2006, Nature). These antigens are critical therapeutic targets because GSCs are notoriously resistant to standard treatments such as temozolomide and ionizing radiation, often serving as the primary drivers of tumor recurrence (Chen et al., 2012, Nature). Immunotherapeutic approaches, most notably dendritic cell vaccines like ICT-107, utilize a panel of GSC-TAAs—including MAGE-1, HER2, AIM-2, TRP-2, gp100, and IL13Rα2—to prime the patient's immune system to recognize and destroy these resilient cells (Phuphanich et al., 2013, Cancer Immunology, Immunotherapy). By targeting the stem cell compartment rather than just the bulk tumor mass, these therapies aim to prevent relapse and extend overall survival in patients with malignant gliomas. However, the clinical efficacy of targeting GSC-TAAs is often challenged by the high degree of molecular heterogeneity within the tumor and the protective, immunosuppressive environment of the central nervous system (Lim et al., 2018, CA: A Cancer Journal for Clinicians).

Other names

Glioblastoma stem cell antigensGSC antigensGlioma stem cell-associated antigensGSC-associated TAAs

Induction of a multi-antigen-specific cytotoxic T-lymphocyte (CTL) response designed to target and eliminate the self-renewing glioblastoma stem cell population.